Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The tyrosine kinase inhibitor dasatinib was added to docetaxel in the treatment of advanced castration-resistant prostate cancer in a Phase 1-2 trial. The combination was shown to be generally well-tolerated and to result in markers of reduced bone turnover in the great majority of patients and in durable PSA responses in approximately 50%. The findings justify proceeding to Phase 3 clinical trial.

Promising Results with Dasatinib Added to Docetaxel for Treating Castration-resistant Prostate Cancer